Trial
NCT02749708
Study of IRX5183 in Relapsed and Refractory Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborators
Io Therapeutics
Condition
Acute Myeloid Leukemia (AML)
Intervention
IRX5183
Why stopped
Study drug supply expired and could not be renewed.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-04-22